Currently, there are 261.64M common shares owned by the public and among those 251.87M shares have been available to trade.
The company’s stock has a 5-day price change of 14.62% and 103.11% over the past three months. AKBA shares are trading 106.32% year to date (YTD), with the 12-month market performance up to 266.36% higher. It has a 12-month low price of $0.80 and touched a high of $4.08 over the same period. AKBA has an average intraday trading volume of 5.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 26.74%, 56.60%, and 98.43% respectively.
Institutional ownership of Akebia Therapeutics Inc (NASDAQ: AKBA) shares accounts for 36.53% of the company’s 261.64M shares outstanding.
It has a market capitalization of $1.03B and a beta (3y monthly) value of 0.85. The earnings-per-share (ttm) stands at -$0.22. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.47% over the week and 3.32% over the month.
Earnings per share for the fiscal year are expected to increase by 80.61%, and 215.62% over the next financial year.
Looking at the support for the AKBA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 04, 2025, with the firm’s price target at $8. Leerink Partners coverage for the Akebia Therapeutics Inc (AKBA) stock in a research note released on April 28, 2025 offered a Outperform rating with a price target of $7. Jefferies was of a view on April 01, 2025 that the stock is Buy, while BTIG Research gave the stock Buy rating on November 29, 2023, issuing a price target of $4. H.C. Wainwright on their part issued Buy rating on August 28, 2023.
